AU4009899A - Molecules targeting cd40 and tumor cells - Google Patents

Molecules targeting cd40 and tumor cells

Info

Publication number
AU4009899A
AU4009899A AU40098/99A AU4009899A AU4009899A AU 4009899 A AU4009899 A AU 4009899A AU 40098/99 A AU40098/99 A AU 40098/99A AU 4009899 A AU4009899 A AU 4009899A AU 4009899 A AU4009899 A AU 4009899A
Authority
AU
Australia
Prior art keywords
tumor cells
molecules targeting
targeting
molecules
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU40098/99A
Inventor
David W Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanox Inc
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox Inc filed Critical Tanox Inc
Publication of AU4009899A publication Critical patent/AU4009899A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
AU40098/99A 1998-05-23 1999-05-21 Molecules targeting cd40 and tumor cells Abandoned AU4009899A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8662398P 1998-05-23 1998-05-23
US60086623 1998-05-23
PCT/US1999/011421 WO1999061057A2 (en) 1998-05-23 1999-05-21 Molecules targeting cd40 and tumor cells

Publications (1)

Publication Number Publication Date
AU4009899A true AU4009899A (en) 1999-12-13

Family

ID=22199807

Family Applications (1)

Application Number Title Priority Date Filing Date
AU40098/99A Abandoned AU4009899A (en) 1998-05-23 1999-05-21 Molecules targeting cd40 and tumor cells

Country Status (2)

Country Link
AU (1) AU4009899A (en)
WO (1) WO1999061057A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3662101A (en) * 2000-02-01 2001-08-14 Tanox Inc Cd40-binding apc-activating molecules
AR039067A1 (en) * 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
GB0512225D0 (en) * 2005-06-16 2005-07-27 Univ Sheffield Immunoglobulin molecules
MX349057B (en) 2010-11-30 2017-07-07 Chugai Pharmaceutical Co Ltd Cytotoxicity-inducing therapeutic agent.
RU2722788C2 (en) 2014-04-07 2020-06-03 Чугаи Сейяку Кабусики Кайся Immunoactivating antigen-binding molecule
MX2016014434A (en) 2014-05-13 2017-02-23 Chugai Pharmaceutical Co Ltd T cell-redirected antigen-binding molecule for cells having immunosuppression function.
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
EP3378488A4 (en) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
SG11201810509PA (en) 2016-06-20 2018-12-28 Kymab Ltd Anti-pd-l1 antibodies
US11773180B2 (en) 2017-11-08 2023-10-03 Kyowa Kirin Co., Ltd. Bispecific antibody which binds to CD40 and EpCAM
WO2020127376A2 (en) * 2018-12-17 2020-06-25 Alligator Bioscience Ab Novel polypeptides
US20220259328A1 (en) 2019-05-15 2022-08-18 Kyowa Kirin Co., Ltd. Bispecific antibody binding to cd40 and fap
TW202108625A (en) 2019-05-15 2021-03-01 日商協和麒麟股份有限公司 Bispecific antibody capable of binding to cd40 and gpc3

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1997894B1 (en) * 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker

Also Published As

Publication number Publication date
WO1999061057A3 (en) 2000-04-06
WO1999061057A2 (en) 1999-12-02

Similar Documents

Publication Publication Date Title
AU1803601A (en) Methods and compositions for the introduction of molecules into cells
AU2113599A (en) Human protease molecules
AU3560399A (en) Tumor associated nucleic acids and uses therefor
AU4831399A (en) Leafy cotyledon1 genes and their uses
AU5279800A (en) Ion exchange resins and methods of making the same
AU3818300A (en) Treating hair by targeting enzymes
AU715620C (en) Therapeutic methods and uses
AU4009899A (en) Molecules targeting cd40 and tumor cells
AU4823599A (en) Prostate cancer-associated genes
AU1184399A (en) Therapeutic molecules
AU5874798A (en) Vaccination methods and molecules
AU7729498A (en) Methods and uses for transposon-based gene targeting
AU2238499A (en) Androgen-metabolic gene mutations and prostate cancer risk
AU6254799A (en) Anti-ige gene therapy
AU2587399A (en) Human transport-associated molecules
AU2506499A (en) Cea/nca-based differentiation cancer therapy
AU4629399A (en) Substituted piperazones and their therapeutic uses
AU5946999A (en) Tumour therapy and imaging
AU4860299A (en) (zap-3) tumor associated genes and their uses
AUPP263498A0 (en) Novel therapeutic molecules and uses therefor
AU5429699A (en) Drug targeting
AU3349997A (en) Reg gene expression in cancer tissue
AU2591099A (en) Human proteinase molecules
AU2044001A (en) Targeted bifunctional molecules and therapies based thereon
AU4050999A (en) Genes and enzymes

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase